Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

A groundbreaking £1.65million gene therapy treatment offering hope for sickle cell disease patients has been approved for use ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

After moving from Sierra Leone to London, guest columnist Richard Bayliss received a proper diagnosis and care plan for his sickle cell.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...